1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Time Is On Eisai’s Side As More Long-Term Data Emerge For Leqembi

Dual Action Stands Out From Lilly’s Kisunla

 
• By Mandy Jackson

Leqembi for early Alzheimer’s disease now has an anti-amyloid competitor in the US with limited-term dosing, but new data at AAIC support chronic dosing of Eisai’s Biogen-partnered drug.

Caregiver cheers up senior lady patient touching hand while sits in armchairs in light room
Maintenance and subcutaneous dosing could reduce the burden of chronic Leqembi treatment • Source: Shutterstock

New long-term data on Eisai Co., Ltd./Biogen, Inc.’s early Alzheimer’s disease medicine Leqembi (lecanemab) presented at the Alzheimer’s Association International Conference (AAIC) indicate that chronic treatment has a better effect than short-term treatment, possibly negating what was thought to be a potential advantage for Eli Lilly and Company’s competing anti-amyloid antibody Kisunla (donanemab).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

More from R&D

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 
• By Andrew McConaghie, Edwin Elmhirst, and Dexter Jie Yan

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.